Evidence map›Paper›PMID 30564426›Full record

ArticleRoyal Society open science2018

Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy.

Shuqian Wan, Long Zhang, Yunyun Quan, Kun Wei

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Royal Society open science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024
    Review
  18. Article
  19. Review
  20. Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Shuqian WanSchool of Biological Science and Engineering, South China University of Technology, Guangzhou 510640, People's Republic of China.ORCID 0000-0003-2032-2640
Long ZhangWenzhou Institute of Biomaterials and Engineering, CAS, Wenzhou, Zhejiang 325011, People's Republic of China.
Yunyun QuanWenzhou Institute of Biomaterials and Engineering, CAS, Wenzhou, Zhejiang 325011, People's Republic of China.
Kun WeiSchool of Biological Science and Engineering, South China University of Technology, Guangzhou 510640, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (3, 4', 5-trihydroxy-

Indexed as

bioactivitynon-alcoholic fatty liver diseasePLGA nanoparticlesresveratrolsolubilitystability

Identifiers

PMID30564426
PMCPMC6281916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.